Sophiris Bio (NASDAQ: SPHS) is one of 103 public companies in the “Pharmaceuticals” industry, but how does it compare to its rivals? We will compare Sophiris Bio to similar businesses based on the strength of its profitability, earnings, risk, valuation, institutional ownership, dividends and analyst recommendations.


This table compares Sophiris Bio and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sophiris Bio N/A -85.20% -38.89%
Sophiris Bio Competitors -464.97% -56.13% -6.97%

Analyst Ratings

This is a breakdown of recent ratings and target prices for Sophiris Bio and its rivals, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sophiris Bio 0 0 4 0 3.00
Sophiris Bio Competitors 863 3771 6731 178 2.54

Sophiris Bio presently has a consensus target price of $6.25, indicating a potential upside of 197.62%. As a group, “Pharmaceuticals” companies have a potential upside of 22.75%. Given Sophiris Bio’s stronger consensus rating and higher possible upside, analysts clearly believe Sophiris Bio is more favorable than its rivals.

Earnings and Valuation

This table compares Sophiris Bio and its rivals gross revenue, earnings per share and valuation.

Gross Revenue NetIncome Price/Earnings Ratio
Sophiris Bio N/A -$11.16 million -16.15
Sophiris Bio Competitors $8.17 billion $1.09 billion 104.80

Sophiris Bio’s rivals have higher revenue and earnings than Sophiris Bio. Sophiris Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Institutional & Insider Ownership

5.9% of Sophiris Bio shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.9% of Sophiris Bio shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility & Risk

Sophiris Bio has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Sophiris Bio’s rivals have a beta of 39.14, meaning that their average share price is 3,814% more volatile than the S&P 500.


Sophiris Bio rivals beat Sophiris Bio on 8 of the 12 factors compared.

About Sophiris Bio

Sophiris Bio, Inc., formerly Protox Therapeutics Inc., is a Canada-based biopharmaceutical company focused on the research, development and commercialization of products for the treatment of urological diseases. The Company has operations based in San Diego developing a treatment for benign prostatic hyperplasia (benign prostatic hyperplasia (BPH) or enlarged prostate). The Company has partnered with Kissei Pharmaceuticals for the development and commercialization of PRX302 in Japan. Sophiris Bio, Inc. is advancing a pipeline of receptor targeted fusion proteins based on three complementary technology platforms: PORxin, INxin and HUMxin. It focuses on diseases of the prostate via its PORxin platform candidate, PRX302, which has completed three clinical trials for the treatment of BPH, as well as two clinical trials for the treatment of localized recurrent prostate cancer.

Receive News & Ratings for Sophiris Bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sophiris Bio Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.